Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.

Biotechnology

Allogene Therapeutics

David Chang

Susan Gaffud

Hien do

Marissa D'Inca

Debbie W.

Karen Garry

Janet Lee

Wenjing Li

Upendra Chitgupi

Steven J.

Sindy Mancuso

Aastha Shrestha

Quentin Smith

Pratiksha Dighe

Nga Chan

Melanie G.

Mark O'Dair

Marie Anand

Marcel Meury

Lyubov Efros

Lily Wong

Lilian Wang

Kristen Zhang

Kim Gorrell

Jin Yang

Hayung Y.

Elizabeth C.

Elissa Bloom

Devin Otto

Cyrille Dana Madarang

Bennett Alphson

Danielle Dishmon

Peng Cui

Zachary J Roberts M.D.

Taylor Karst

Hsin-Yuan Cheng

Ho Chuen Lau

Peter Schow

Wei-Meng Zhao

Eike Zimmermann

Monique D.

Earl Douglas

Tim Moore

Stephen Hardt

Zachary J. Roberts

Susan Lundeen

Christine Cassiano

The Scientific Research Team at Allogene Therapeutics focuses on pioneering and advancing the development of AlloCAR T™ therapies for cancer. Comprised of experts in various scientific disciplines, the team conducts preclinical and clinical research, optimizes cell engineering techniques, and develops innovative analytical methods to improve the efficacy, reliability, and scalability of allogeneic CAR T cell therapies for "off-the-shelf" use.

Scientific Research Team

Clinical Operations and Program Management

Scientific and Research Team

Scientific Research Team

About

Team members

Other teams at Allogene Therapeutics

Clinical Operations and Program Management

Scientific and Research Team